Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DR26FDJC6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,766
Award facts
- Contract value 100% obligated
- $12,766.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,766.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. The award, issued on November 12, 2025, with an ultimate completion date of November 13, 2025, carries no set-aside designation, indicating the contractor won on a competitive basis. DMS Pharmaceutical Group is registered as a single-award indefinite delivery contractor under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure reliable pharmaceutical supply chains for Department of Defense healthcare operations globally.
This delivery order exemplifies the operational execution of the PPV-G GEN V contract vehicle, which authorizes DLA to issue firm fixed-price orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The broader PPV-G GEN V indefinite delivery contract held by DMS Pharmaceutical Group carries a ceiling value of $499,999,999 through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's extensive product portfolio, which includes oncology treatments, specialty pharmaceuticals, biologics, and routine medications, positions the company as a critical supplier within the federal military medical system's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FDJC6?
SPE2DR26FDJC6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DR26FDJC6 worth?
The government has obligated $12,766 on SPE2DR26FDJC6.
Is contract SPE2DR26FDJC6 an order under another contract?
Yes. SPE2DR26FDJC6 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJC6 competed?
The extent of competition for SPE2DR26FDJC6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award